Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Molecular Partners ( (MOLN) ) is now available.
On October 30, 2025, Molecular Partners announced its Q3 2025 financial results and clinical progress, highlighting the filing of an IND application for MP0712, a Radio-DARPin targeting DLL3, with a Phase 1 trial expected to start by the end of 2025. The company also shared updates on other programs, including MP0533 for AML and MP0317 for cholangiocarcinoma, alongside a strong financial position with a cash runway until 2028. These developments reflect Molecular Partners’ strategic advancements in oncology, potentially enhancing its industry standing and offering significant implications for stakeholders.
The most recent analyst rating on (MOLN) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.
Spark’s Take on MOLN Stock
According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.
The overall stock score of 42 reflects significant financial challenges, including declining revenue and negative profitability, which are the most impactful factors. Technical analysis indicates a bearish trend with potential oversold conditions, while valuation concerns are heightened by a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on MOLN stock, click here.
More about Molecular Partners
Molecular Partners AG is a clinical-stage biotech company based in Zurich-Schlieren, Switzerland, specializing in the development of DARPin therapeutics, a new class of custom-built protein drugs. The company focuses on innovative treatments for cancer and other serious diseases, leveraging its expertise in protein engineering to create novel therapeutic modalities.
Average Trading Volume: 3,242
Technical Sentiment Signal: Sell
Current Market Cap: $149M
For a thorough assessment of MOLN stock, go to TipRanks’ Stock Analysis page.